Starling Oncology annual return on equity
2021
2022
2023
2024
Starling Oncology Return on Equity (ROE) Growth & History (STLN)
Starling Oncology's return on equity was −213.36% for fiscal 2024.
View full Starling Oncology company overviewStarling Oncology annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −213.36% | −121.16 pp |
| 2023 | 2023-12-31 | −92.20% | −92.33 pp |
| 2022 | 2022-12-31 | 0.13% | +16.66 pp |
| 2021 | 2021-12-31 | −16.52% | — |
Starling Oncology quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2025 | 2025-03-31 | −452.41% | −411.96 pp |
| Q4 2024 | 2024-12-31 | −138.24% | −109.14 pp |
| Q3 2024 | 2024-09-30 | −72.11% | −49.86 pp |
| Q2 2024 | 2024-06-30 | −43.91% | −25.46 pp |
| Q1 2024 | 2024-03-31 | −40.46% | −13.38 pp |
| Q4 2023 | 2023-12-31 | −29.10% | −20.34 pp |
| Q3 2023 | 2023-09-30 | −22.25% | −20.13 pp |
| Q2 2023 | 2023-06-30 | −18.45% | −14.19 pp |
| Q1 2023 | 2023-03-31 | −27.08% | −43.41 pp |
| Q4 2022 | 2022-12-31 | −8.77% | +4.62 pp |
| Q3 2022 | 2022-09-30 | −2.12% | +3.96 pp |
| Q2 2022 | 2022-06-30 | −4.26% | −10.83 pp |
| Q1 2022 | 2022-03-31 | 16.33% | +18.98 pp |
| Q4 2021 | 2021-12-31 | −13.39% | +244.73 pp |
| Q3 2021 | 2021-09-30 | −6.09% | — |
| Q2 2021 | 2021-06-30 | 6.57% | — |
| Q1 2021 | 2021-03-31 | −2.65% | — |
| Q4 2020 | 2020-12-31 | −258.12% | — |
Starling Oncology return on equity trends
Between the periods ended 2021-12-31 and 2024-12-31, Starling Oncology's return on equity decreased from −16.52% to −213.36%, a change of −196.84 percentage points. The latest reported quarter, Q1 2025, shows −452.41%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Starling Oncology source filings ↗